Frequently Asked Questions
The market is segmented based on , By Types (Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML)and Others), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Myeloid Leukemia Treatment Market size was valued at USD 16.00 USD Million in 2022.
The Global Myeloid Leukemia Treatment Market is projected to grow at a CAGR of 10% during the forecast period of 2023 to 2030.
The major players operating in the market include F. Hoffmann, La Roche , Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GSK plc, Novartis AG, Bayer AG, Merck & Co., Cipla , Abbott, AbbVie , Sun Pharmaceutical Industries , Aurobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Viracta Therapeutics, .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
